Clinical trials: Resistant Major Depression
Major Depressive Disorder
Ketamine Infusion for Treatment-resistant Major Depressive Disorder
Ketamine infusion has been shown to have rapid antidepressant properties, however the possible use of ketamine in treatment-resistant depression as augmentation has not been investigated.
- Trial name
- NCT01582945
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Treatment Resistant Depression, Major Depressive Disorder
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression
In this proof of concept study, the investigators plan to administer iv ketamine interleaved with ECT days. Patients with treatment resistant depression who are deemed to be eligible for ECT treatment will randomly be assigned to…
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT02522377
- Testing
- Ketamine, Midazolam
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- The Cleveland Clinic
Major Depressive Disorder, Treatment Resistant Depression
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses.
- Trial name
- INTENSIFY MDD (NCT05973851)
- Testing
- Esketamine Nasal Product, Ketamine Hydrochloride, Esketamine hydrochloride
- Where
- 12 sites in Austria, Germany and 4 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Depression
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication…
- Trial name
- NCT00021528
- Testing
- citalopram, BuproprionSR, buspirone
- Where
- 41 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- National Institute of Mental Health (NIMH)
Depression, Major Depressive Disorder
Reward Emotion Learning and Ketamine Study
Ketamine's efficacy as an antidepressant is now well established yet the mechanisms underlying its antidepressant effect are yet to be fully described.
- Conditions
- Depression, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- RELAKS (NCT04850911)
- Testing
- Ketamine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Major Depression
Transcranial Magnetic Stimulation (rTMS) Accelerates the Response to Escitalopram in Major Depression
A doubleblind randomised trial with active versus sham rTMS in combination with escitalopram in patients with prior treatment resistant depression in an acute 12 weeks trial with subsequent 24 weeks study phase with active versus…
- Trial name
- NCT00149071
- Testing
- rTMS, TMS
- Where
- Denmark
- Volunteers
- 61 people
- Sponsor
- Hillerod Hospital, Denmark
Healthy, Major Depressive Disorder
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome.
- Conditions
- Healthy, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- NCT06480201
- Testing
- Ketamine, Saline
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Unipolar Depression
Repetitive Transcranial Magnetic Stimulation and Venlafaxine in Depression
The purpose of this study is to assess the efficacy of add-on therapy with repetitive Transcranial Magnetic Stimulation (rTMS) and venlafaxine in the treatment of major depressive disorders compared to venlafaxine only (the…
- Trial name
- NCT00714090
- Testing
- active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed
- Where
- 18 sites in France, Monaco
- Volunteers
- 170 people
- Sponsor
- Club rTMS et Psychiatrie
Major Depressive Disorder
Practicing Alternative Techniques to Heal From Depression: The PATH-D Study
This study is a randomized, controlled trial of Mindfulness-Based Cognitive Therapy (MBCT) versus Health-Enhancement Program (HEP) for patients with treatment-resistant major depressive disorder (MDD).
- Trial name
- PATH-D (NCT00871299)
- Testing
- Mindfulness Based Cognitive Therapy, Health Enhancement Program and medication management
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder, Bipolar Disorder
Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)
Background: People with TRD are often helped by electroconvulsive therapy (ECT). But ECT can affect memory and thinking. Researchers want to study a treatment called TEST that uses less electricity.
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
- Trial name
- NCT05172271
- Testing
- MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Mental Health (NIMH)
Post-Traumatic Stress Disorders, Major Depressive Disorder
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
Co-occurring post-traumatic stress disorder (PTSD) and major depressive disorder (MDD) is the most common response to trauma; it is associated with poor clinical outcomes and substantial human disability.
- Trial name
- NCT04032301
- Testing
- Ketamine, Normal Saline
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Treatment Resistant Depression
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major…
- Trial name
- NCT06524830
- Testing
- VLS-01-203 BU
- Where
- 48 sites in United States, Australia and 2 more
- Volunteers
- 142 people
- Sponsor
- atai Therapeutics, Inc.
Major Depressive Disorder
Pilot Study in Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depression
The purpose of this study is to assess the efficacy of a Deep Shaped-Field repetitive transcranial magnetic stimulation (DSF-rTMS) system in the treatment of depression.
- Trial name
- NCT01431001
- Testing
- Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)
- Where
- 4 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Cervel Neurotech, Inc.
Treatment Resistant Depression
Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality
In this study we will assess the effect of Ketamine infusion on depressive symptoms and in particular its effect on Suicidal behavior, ideation and thoughts in patients with treatment- resistant MDD.
- Trial name
- NCT04101474
- Testing
- Ketamine
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Assiut University
Depression
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression
This study aims to examine the antidepressant efficacy of riluzole, employing a randomized, double-blind, placebo-controlled, adjunctive trial in treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT01204918
- Testing
- Riluzole
- Where
- 3 sites in United States
- Volunteers
- 104 people
- Sponsor
- Yale University
Behavioral Symptoms, Suicide
Natural History of Depression, Bipolar Disorder and Suicide Risk
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments.
- Conditions
- Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents
- Trial name
- NCT06462196
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depression
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S.
- Trial name
- PIVOT (NCT07226232)
- Testing
- Psilocybin
- Where
- 5 sites in United States
- Volunteers
- 240 people
- Sponsor
- VA Office of Research and Development
Depression, Treatment Resistant Depression
Mindfulness Engaged Neurostimulation for Depression
Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region.
- Conditions
- Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
- Trial name
- MEND I (NCT06399406)
- Testing
- Medi-TBS
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Diego
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Accelerated iTBS for Major Depression
Major depressive disorder (MDD) is a common and disabling psychiatric condition, and many patients do not achieve adequate response to standard antidepressant treatments.
- Trial name
- AIM-D (NCT07603804)
- Testing
- Accelerated Intermittent Theta Burst Stimulation (iTBS)
- Where
- Turkey (Türkiye)
- Volunteers
- 35 people
- Sponsor
- Istanbul University - Cerrahpasa
Obesity, Major Depressive Disorder
Comorbid Obesity and Depression With an Anti-inflammatory Medication
Research suggests that only a subset of individuals with major depressive disorder (MDD) may benefit from anti-inflammatory treatments: those who have C-reactive protein (CRP) ≥3 mg/L, a commonly used threshold for "low-grade"…
- Conditions
- Obesity, Major Depressive Disorder, Inflammation
- Trial name
- CODA (NCT06537921)
- Testing
- Minocycline 200mg
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- King's College London